Previous investigations on the pro-invasive actions of FRA1 in CRC have used the BE cell line model, which comprises highly invasive mesenchymal-like cells that harbor KRAS/BRAF mutations driving high endogenous FRA1 expression [33], [37]. The gene discussed is KRAS; the disease is colorectal carcinoma.